Heron Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 9, 2026, 8:15 a.m. ETView on SEC.gov Our explainer
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedHeron Therapeutics Q3 2026 revenue of $35.3 million misses $37.5 million consensus; EPS -$0.03 vs -$0.025 expected; no guidance, company selling substantially all assets to CorMedix
8-KNov. 9, 2026, 7:40 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Material modification of security holders' rights · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedHeron Therapeutics to Sell Substantially All Assets to CorMedix for $145.0 Million Cash Plus 14,583,333 CorMedix Shares, Wind Down Operating Business
8-KSept. 29, 2026, 5 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
8-KAug. 14, 2026, 4:30 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Material modification of security holders' rights · Financial statements and exhibits
8-KAug. 10, 2026, 8 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits